Procerin™, another fairly well-known hair loss treatment brand appears to be based on a mix of natural substances — and claimed to treat pattern hair loss by purportedly inhibiting the conversion of testosterone to DHT. Procerin™ is available in an ingestible tablet and a liquid foam. The purveyors of this product line claim to have substantiation via what they describe as “an IRB approved study”.
Here is why such a claim appears to our eye to be nonsensical. In the vernacular, an IRB study means a study “monitored” by an entity known as an Institutional Review Board (IRB). Institutional Review Boards are independent quasi-governmental entities tasked with closely monitoring medical research trials to ensure that the study-site, study protocol, and study investigator(s) comply with the highest standards of safety and objectivity. Each IRB is a known, named entity. For instance, WIRB stands for Western Institutional Review Board, a review service operating out of Olympia, Washington (www.wirb.com). Typically, an IRB study will test a reagent or composition via placebo-controlled, double-blind conditions where the neither the investigator nor the treated subjects are aware which material is being administered, the active treatment agent or a sham placebo.
IRB studies are generally conducted at FDA-regulated Contract Research Organizations (CRO’s) such as a sponsor-site, research clinic, university or hospital. Each trial is supported with audit-ready Case Report Forms (CRF’s), and these are retained as source documentation for a fixed period of time. A CRF will typically contain an exhaustive amount of data, from which an encyclopedia volume could be created.
Thus, Institutional Review Boards, by their very nature “monitor” research studies, they do not “approve” them. Moreover, the typical pathway followed in an IRB-monitored study involves critical peer review and, if the study is deemed scientifically noteworthy, publication in the peer-reviewed medical literature. Scientifically-valid peer-reviewed studies are found on pubmed.com.
Let us be clear. An IRB’s function is to monitor research, not approve it. Therefore, to refer to any piece of research as an IRB-approved study is to utter a non sequitor. Simply put, to our knowledge there is no such thing as an IRB-approved study. There are IRB-monitored studies and there’s everything else. Either one’s study is IRB-monitored or it is not. Likewise, either someone’s study is published in the peer-reviewed medical literature, or it is not. There’s no ‘sorta kinda peer-reviewed’ system operating in the scientific medical world. Perhaps we are missing something that mitigates, but in the case of Procerin™, we have difficulty comprehending what they are trying to accomplish by characterizing their product as IRB-approved, other than to ape HairGenesis® by purporting the achievement of something they’ve not actually achieved.
In contrast, the drug-free formulations comprising HairGenesis® have been successfully tested under numerous well-designed studies, notably an IRB-monitored, placebo-controlled, double blind, randomized, peer-reviewed and published trial. Additionally, HairGenesis® is supported with an ongoing R&D infrastructure which has resulted in the development of seven distinct generations of continually-improved formulations.
Partnering with university-based research collaborators at State University, New York (SUNY) and elsewhere, HairGenesis® has developed proprietary systems wherein dual-mechanisms of action mean that our formulations work in a synergistic manner to protect and revitalize thinning scalp hair. We’ve also pioneered a proprietary delivery system to optimize the efficiency by which the active substances are taken up by the target hair follicles. As noted, we’ve also backed our hypotheses with critically peer-reviewed and published data. And there are patents pending on the landmark discoveries we’ve made.
Of note, our latest formulas have been shown to block micro-inflammation of the hair follicle as well as inhibit the negative consequences of 5 alpha dihydrotestosterone — a pathogenic metabolite of the steroid hormone testosterone (T). This means that HairGenesis® demonstrably helps revitalize your hair in more than one way. While consistently excellent clinical results are now possible for a broad spectrum of hair loss affected individuals, because HairGenesis® is run by hair loss experts, not marketers, you can expect the results you achieve to get even better as our R&D leads to the development of ever more effective treatment formulas. With a client base that spans all six populated continents, those who use HairGenesis® have come to understand how uniquely safe and powerful our PRODUCTS really are. Many clients have been with us for more than ten years and will simply not be without their HairGenesis® PRODUCTS. So when it comes to trusting the health of your hair, choose wisely — choose HairGenesis®.